Related Experiment Video
Updated: Jul 15, 2026
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
Published on: January 6, 2014
TGF-beta insensitive dendritic cells: an efficient vaccine for murine prostate cancer
Fu-Li Wang1, Wei-Jun Qin, Wei-Hong Wen
1Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Abstract:
Dendritic cells (DCs) are highly potent initiators of the immune response, but DC effector functions are often inhibited by immunosuppressants such as transforming growth factor beta (TGF-beta). The present study was conducted to develop a treatment strategy for prostate cancer using a TGF-beta-insensitive DC vaccine. Tumor lysate-pulsed DCs were rendered TGF-beta insensitive by dominant-negative TGF-beta type II receptor (TbetaRIIDN), leading to the blockade of TGF-beta signals to members of the Smad family, which are the principal cytoplasmic intermediates involved in the transduction of signals from TGF-beta receptors to the nucleus. Expression of TbetaRIIDN did not affect the phenotype of transduced DCs. Phosphorylated Smad-2 was undetectable and expression of surface co-stimulatory molecules (CD80/CD86) were upregulated in TbetaRIIDN DCs after antigen and TGF-beta1 stimulation. Vaccination of C57BL/6 tumor-bearing mice with the TbetaRIIDN DC vaccine induced potent tumor-specific cytotoxic T lymphocyte responses against TRAMP-C2 tumors, increased serum IFN-gamma and IL-12 level, inhibited tumor growth and increased mouse survival. Furthermore, complete tumor regression occurred in two vaccinated mice. These results demonstrate that blocking TGF-beta signals in DC enhances the efficacy of DC-based vaccines.
Insights
This study developed a novel dendritic cell (DC) vaccine for prostate cancer. By making DCs insensitive to transforming growth factor beta (TGF-beta), the vaccine enhanced anti-tumor immune responses and improved survival in mice.
Area of Science:
- Immunology
- Cancer Biology
- Vaccine Development
Background:
- Dendritic cells (DCs) are crucial for initiating immune responses.
- Immunosuppressive molecules like transforming growth factor beta (TGF-beta) can inhibit DC function.
- Prostate cancer treatments often face challenges due to immunosuppression.
Purpose of the Study:
- To develop a TGF-beta-insensitive DC vaccine for prostate cancer treatment.
- To enhance the anti-tumor efficacy of DC-based immunotherapy.
- To overcome immunosuppression mediated by TGF-beta in the tumor microenvironment.
Main Methods:
- DCs were engineered to express a dominant-negative TGF-beta type II receptor (TbetaRIIDN) to block TGF-beta signaling.
- TbetaRIIDN DCs were pulsed with tumor lysate.
- Vaccination efficacy was assessed in C57BL/6 mice bearing TRAMP-C2 tumors.
Main Results:
- TbetaRIIDN DCs showed no change in phenotype but had undetectable phosphorylated Smad-2 and upregulated co-stimulatory molecules (CD80/CD86) upon stimulation.
- Vaccination with TbetaRIIDN DCs induced potent tumor-specific cytotoxic T lymphocyte (CTL) responses.
- Significant inhibition of tumor growth, increased mouse survival, and elevated serum IFN-gamma and IL-12 levels were observed.
Conclusions:
- Blocking TGF-beta signaling in DCs enhances their function and immunogenicity.
- TGF-beta-insensitive DC vaccines represent a promising strategy for cancer immunotherapy.
- This approach effectively overcomes tumor-induced immunosuppression and promotes anti-tumor immunity.
